Skip navigation
Image Alt

Signatera™ in High Risk Breast Cancer

Changing the management of cancer with personalized testing

Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into your patient's disease. By detecting and quantifying ctDNA, Signatera can optimize your ability to assess risk, predict recurrence, and monitor treatment response in those most at risk for progression.

Sign up to learn more about how Signatera can help your patients.


Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into your patient's disease. By detecting and quantifying ctDNA, Signatera can optimize your ability to assess risk, predict recurrence, and monitor treatment response in those most at risk for progression.

In the Driver’s Seat with Signatera

When Rachelle was diagnosed with breast cancer at age 29, she was a young entrepreneur determined not to let her diagnosis define her. Her passion helped her maintain perspective as she and her doctor created a treatment plan.


Learn how Rachelle worked to integrate Signatera into her care plan and how she became a dedicated patient advocate along the way.

“The confidence of [getting tested with] Signatera allows me to live my best life every day.”

– Rachelle – entrepreneur, advocate, and breast cancer survivor

Unparalleled Insight in High Risk Breast Cancer

Signatera can detect recurrence up to 2 years earlier than traditional imaging.1

Signatera predicts breast cancer recurrence earlier and with greater accuracy than traditional tools by using a highly-personalized molecular residual disease assay.1

Neoadjuvant

What can ctDNA tell you about your patient’s risk?

Surveillance

Is there a better way to monitor your patient?

Metastatic

Is the tumor responding to immunotherapy?

Signatera on Radio

Signatera on Radio

Listen to Natera Leadership discuss how Signatera can help breast cancer patients on Into Tomorrow with Dave Graveline

Signatera on TV

Learn about a TNBC patient’s experience with Signatera on GMA

Signatera on radio

Signatera on Radio

Listen to a recent story from NPR about how Signatera can be used in different tumor types

Is Signatera right for your patients?

We’re here to help you find out



References

1Coombes RC, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. https://doi.org/10.1158/1078-0432.CCR-18-3663